These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29451914)

  • 1. Correction: Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Chiu CC; Lu ML; Huang MC; Chen PY; Lin YK; Lin SK; Chen CH
    PLoS One; 2018; 13(2):e0193315. PubMed ID: 29451914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Chiu CC; Lu ML; Huang MC; Chen PY; Lin YK; Lin SK; Chen CH
    PLoS One; 2016; 11(12):e0168347. PubMed ID: 27973619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study.
    Chen CH; Huang MC; Kao CF; Lin SK; Kuo PH; Chiu CC; Lu ML
    J Clin Psychiatry; 2013 May; 74(5):e424-30. PubMed ID: 23759461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.
    Carrizo E; Fernández V; Connell L; Sandia I; Prieto D; Mogollón J; Valbuena D; Fernández I; de Baptista EA; Baptista T
    Schizophr Res; 2009 Aug; 113(1):19-26. PubMed ID: 19515536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Relationships of Obesity-Related Genetic Variants With Metabolic Profiles and Response to Metformin in Clozapine-Treated Patients With Schizophrenia.
    Chen PY; Lu ML; Huang MC; Kao CF; Kuo PH; Chiu CC; Lin SK; Chen CH
    J Clin Psychopharmacol; 2015 Oct; 35(5):574-8. PubMed ID: 26263223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.
    Fleischhacker WW; Heikkinen ME; Olié JP; Landsberg W; Dewaele P; McQuade RD; Loze JY; Hennicken D; Kerselaers W
    Int J Neuropsychopharmacol; 2010 Sep; 13(8):1115-25. PubMed ID: 20459883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study.
    Nielsen J; Emborg C; Gydesen S; Dybbro J; Aagaard J; Haderup K; Glyngdal P; Fabricius S; Thode D; Lublin H; Andersen T; Damkier P; Taylor D
    J Clin Psychopharmacol; 2012 Apr; 32(2):173-8. PubMed ID: 22367659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Josiassen RC; Joseph A; Kohegyi E; Stokes S; Dadvand M; Paing WW; Shaughnessy RA
    Am J Psychiatry; 2005 Jan; 162(1):130-6. PubMed ID: 15625211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction: Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial.
    Wise RA; Holbrook JT; Criner G; Sethi S; Rayapudi S; Sudini KR; Sugar EA; Burke A; Thimmulappa R; Singh A; Talalay P; Fahey JW; Berenson CS; Jacobs MR; Biswal S;
    PLoS One; 2017; 12(3):e0175077. PubMed ID: 28350841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study.
    Muscatello MR; Bruno A; Pandolfo G; Micò U; Scimeca G; Di Nardo F; Santoro V; Spina E; Zoccali RA
    Schizophr Res; 2011 Apr; 127(1-3):93-9. PubMed ID: 21262565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study.
    Motoya S; Watanabe K; Ogata H; Kanai T; Matsui T; Suzuki Y; Shikamura M; Sugiura K; Oda K; Hori T; Araki T; Watanabe M; Hibi T
    PLoS One; 2019; 14(4):e0215491. PubMed ID: 30973957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction: Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial.
    Navarro VJ; Belle SH; D'Amato M; Afdhal N; Brunt EM; Fried MW; Rajender Reddy K; Wahed AS; Harrison S;
    PLoS One; 2019; 14(10):e0223915. PubMed ID: 31600349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study.
    Patel AT; Lew MF; Dashtipour K; Isaacson S; Hauser RA; Ondo W; Maisonobe P; Wietek S; Rubin B; Brashear A
    PLoS One; 2021; 16(4):e0250475. PubMed ID: 33852647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison.
    Kumra S; Kranzler H; Gerbino-Rosen G; Kester HM; De Thomas C; Kafantaris V; Correll CU; Kane JM
    Biol Psychiatry; 2008 Mar; 63(5):524-9. PubMed ID: 17651705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study.
    Muscatello MR; Pandolfo G; Micò U; Lamberti Castronuovo E; Abenavoli E; Scimeca G; Spina E; Zoccali R; Bruno A
    J Clin Psychopharmacol; 2014 Feb; 34(1):129-33. PubMed ID: 24145221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
    Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G
    Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
    Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
    J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-Blind, Randomized, Placebo-Controlled Trial of Metoclopramide for Hypersalivation Associated With Clozapine.
    Kreinin A; Miodownik C; Mirkin V; Gaiduk Y; Yankovsky Y; Bersudsky Y; Lerner PP; Bergman J; Lerner V
    J Clin Psychopharmacol; 2016 Jun; 36(3):200-5. PubMed ID: 27028980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial.
    Fleming R; Hopkinson ZE; Wallace AM; Greer IA; Sattar N
    J Clin Endocrinol Metab; 2002 Feb; 87(2):569-74. PubMed ID: 11836287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial.
    Tchoukhine E; Takala P; Hakko H; Raidma M; Putkonen H; Räsänen P; Terevnikov V; Stenberg JH; Eronen M; Joffe G
    J Clin Psychiatry; 2011 Mar; 72(3):326-30. PubMed ID: 20816037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.